We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · November 10, 2022

Efficacy and Safety of Tocilizumab in Adult-Onset Still's Disease

Seminars in Arthritis and Rheumatism


Additional Info

Seminars in Arthritis and Rheumatism
Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry
Semin. Arthritis Rheum. 2022 Aug 30;57(2022)152089, J Sota, A Vitale, G Lopalco, RMR Pereira, HF Giordano, IPB Antonelli, J Makowska, O Brzezińska, A Lewandowska-Polak, P Ruscitti, P Cipriani, ID Cola, M Govoni, F Ruffili, PP Sfikakis, K Laskari, G Ragab, MA Hussein, S Gentileschi, C Gaggiano, F La Torre, A Maier, G Emmi, A Marino, F Ciccia, P Sfriso, MC Maggio, E Bartoloni, C Lomater, MT Hegazy, M Tektonidou, MA Dagostin, A Opinc, GD Sebastiani, R Giacomelli, ED Giudice, AN Olivieri, A Tufan, RK Kardas, R Nuzzolese, F Cardinale, E Więsik-Szewczyk, P Veronica, M Tarsia, F Iannone, F Della Casa, C Fabiani, B Frediani, A Balistreri, D Rigante, L Cantarini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading